Safety and Efficacy of IBI306 in Chinese Subjects With Non-familiar Hypercholesterolemia
Status:
Recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
IBI306 is a fully human monoclonal antibody that binds proprotein convertase
substilisin/kexin type 9 (PCSK-9), preventing its interaction with the low-density
lipoprotein cholesterol receptor (LDL-R) and thereby restoring LDL-R recycling and
low-density lipoprotein cholesterol(LDL-C) uptake. This study is being done to investigate
the effects of IBI306 in Chinese people with non-familiar hypercholesterolemia with very high
or high cardiovascular risk. This study will see if IBI306 will reduce low density
lipoprotein cholesterol (LDL-C) in Chinese people who are taking a certain type of
lipid-lowering medication (statins with or without ezetimibe) and whether it causes any side
effects